Phase II trial of a 20-valent pneumococcal conjugate vaccine in healthy children

Phase 2 trial of 20-valent Pneumococcal Polysaccharide Conjugate Vaccine in pneumococcal disease (2 arms), sponsored by Hubei Provincial Center for Disease Control and Prevention. Primary endpoints: Positive rate of IgG antibodies against pneumococcal serotypes after primary immunization and Geometric mean concentration of IgG antibodies against pneumococcal serotypes after primary immunization. Planned start Feb 2025; status: not yet recruiting.